Role of metalloproteinases and their inhibitors in tumors;Rol de las metaloproteinasas y sus inhibidores en patología tumoral

Medicina (Argentina)

Volumn 72, Issue 6, 2012, Pages 495-502

  Coronato, Silvia ^a   Laguens, Graciela ^a,b   Di Girolamo, Vanda ^a,b  

^a Cátedra de Patología B   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Cancer; Extracellular matrix; Metalloproteinases; TIMPs

Indexed keywords

CHEMOKINE; CYTOKINE; GROWTH FACTOR; METALLOPROTEINASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CANCER INVASION; CARCINOGENESIS; EXTRACELLULAR MATRIX; HOMEOSTASIS; METASTASIS; NEOPLASM; TUMOR MICROENVIRONMENT;

CARCINOGENESIS; EXTRACELLULAR MATRIX; HOMEOSTASIS; MATRIX METALLOPROTEINASE INHIBITORS; METALLOPROTEASES; MOLECULAR STRUCTURE; NEOPLASM METASTASIS; TUMOR MICROENVIRONMENT;

EID: 84872137580     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326: 1216-9.
2. Gross J, Lapierre CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 45: 1014-22.
3. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-33.
4. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
5. Moore CS, Crocker SJ. An alternative perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012; 180: 12-6.
6. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008; 40: 1334-47.
7. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008; 19: 34-41.
8. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012; 56: 232-44
9. Harper E and Bloch KJ. The zymogen of tadpole collagenase. Biochemistry 1971; 10: 3041-55.
10. Arvelo F, Cotte C. Metalloproteinases in tumor progression. Invest Clin. 2006; 47: 185-205.
11. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003; 92: 827-39.
12. Cascales Angosto M, Alvarez-Gómez JA. Metaloproteinasas, matriz extracelular y cáncer. An R Acad Nac Farm 2010; 76: 59-84.
13. Flores-Reséndiz D, Castellanos-Juárez E, Benítez-Bribiesca L. Proteases in cancer progression. Gac Med Mex 2009;145: 131-42.
14. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
15. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases.Mol Aspects Med 2008; 29: 258-89.
16. Roy R, Wewer U, Moses M. Exploring the role of ADAM 12 in breast cancer. AACR Meeting Abstracts 2006: 1025.
17. Xiao LJ, Lin P, Lin F, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 2012; 40: 1714-24.
18. Ito I, Fixman ED, Asai K, et al. Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells. Clin Exp Allergy 2009; 39: 1370-80.
19. Park CH, Chung JH. Epidermal growth factor-induced matrix metalloproteinase-1 expression is negatively regulated by p38 MAPK in human skin fibroblasts. J Dermatol Sci 2011; 64: 134-41.
20. Stetler-Stevenson WG. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev 2008; 27: 57-66.
21. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004; 25: 1543-9.
22. Lee YA, Choi HM, Lee SH, et al. Hypoxia differentially affects IL-1β-stimulated MMP-1 and MMP-13 expression of fibroblast-like synoviocytes in an HIF-1α-dependent manner. Rheumatology (Oxford) 2012; 51: 443-50.
23. Schmucker AC, Wright JB, Cole MD, Brinckerhoff CE. Distal interleukin-1β (IL-1β) response element of human matrix metalloproteinase-13 (MMP-13) binds activator protein 1 (AP-1) transcription factors and regulates gene expression. J Biol Chem 2012; 287: 1189-97.
24. Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-98.
25. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-27.
26. Fernández CA, Butterfield C, Jackson G, Moses MA. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 2003; 278: 40989-95.
27. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20: 161-8.
28. Van Damme J, Struyf S, Opdenakker G. Chemokineprotease interaccions in cancer. Semin Cancer Biol 2004; 14: 201-8.
29. García MF, González-Reyes S, González LO, et al. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol 2010; 91: 324-34.
30. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37-43.
31. Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD. Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency. Respir Res 2011; 23: 12:35.
32. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
33. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8.
34. Noël A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008; 19: 52-60.
35. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 2008; 100: 203-29.
36. Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011; 68: 3853-68.
37. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007; 24: 647-56.
38. Decock J, Hendrickx W, Vanleeuw U, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer 2008; 8: 77.
39. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
40. Gonzalez LO, Corte MD, Vazquez J, et al. Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast. Histopathology 2008; 53: 403-15.
41. Rucci N, Sanitǎ P, Angelucci A. Expanding View of the Role of Matrix Metalloproteases in Metastatic Growth. Curr Mol Med 2011; 11: 609-22.
42. Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct 2010; 2010: 985132.
43. Sounni NE, Paye A, Host L, Noël A. MT-MMPS as regulators of vessel stability associated with angiogenesis. Front Pharmacol 2011; 2: 111.
44. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/ Type IV collagenase (MMP-9). J Biol Chem 1997; 272: 28823-25.
45. Lin HC, Chang JH, Jain S, et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001; 42: 2517-24.
46. Kvelborg M, Sanjay A, Frohlich C, Alberchtsen R, Wewer U. ADAM 12 and SRC interactions in cancer. Proc Amer Assoc Cancer Res 2006; 47: 395.
47. Mochizuki S, Tanaka R, Shimoda M, et al. Connective tissue growth factor is a substrate of ADAM28. Biochem Biophys Res Commun 2010; 402: 651-7.
48. Ohtsuka T, Shiomi T, Shimoda M, et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer 2006; 118: 263-73.
49. Giannelli G, Erriquez R, Fransvea E,et al. Proteolytic im - balance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004; 109: 782-5.
50. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-52.
51. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009; 9: 20.
52. Del Casar JM, González LO, Alvarez E, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 2009; 116: 39-52.
53. Jinga DC, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 2006; 10: 499-510.
54. Wang BQ, Zhang CM, Gao W, Wang XF, Zhang HL, Yang PC. Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol 2011; 137: 1525-33.
55. Vizoso FJ, González LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007; 96: 903-11.
56. Kim HJ, Park CI, Park BW, Lee HD, Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006; 47: 333-42.
57. Têtu B, Brisson J, Wang CS, et al. The influence of MMP- 14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006; 8: R28.
58. Del Casar JM, González-Reyes S, González LO, et al. Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol 2010; 136: 811-9.
59. González LO, González-Reyes S, Junquera S, et al. Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events. J Cancer Res Clin Oncol 2010; 136: 1313-21.
60. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clinical Biochemistry 2011; 44: 2.
61. Zhang B, Cao X, Liu Y, et al. Tumor-derived Matrix Metalloproteinase- 13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008; 8: 83-93.
62. Liu XW, Taube ME, Jung KK, et al. Tissue inhibitor of metalloproteinase- 1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005; 65: 898-906.
63. Mylona E, Magkou C, Giannopoulou I, et al. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res 2006; 8: R57.
64. Surlin V, Ioana M, Pleşea IE. Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer. Rom J Morphol Embryol 2011; 52: 231-6.
65. Hong SW, Kang YK, Lee B, et al. Matrix metalloproteinase- 2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 2011; 27: 133-9.
66. Alakus H, Grass G, Hennecken JK, et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 2008; 23: 917-23.
67. Shao W, Wang W, Xiong XG, et al. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA nonsmall cell lung cancer. J Surg Oncol 2011; 104: 841-6.
68. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases Amino Acids 2011; 41: 271-90.
69. Kim EM, Hwang O. Role of matrix metalloproteinase-3 in neurodegeneration. J Neurochem 2011; 116: 22-32.
70. Diaz RJ, Eichten A, de Visser KE, Coussens LM. Matrix Metalloproteinases: mediators of tumour-host cell interactions. In: GG Meadows, ed. Integration/ Interaction of Oncologic Growth, N.York: Springer, 2005, 81-126.
71. Bauvois B. New facets of matrix metalloproteinases MMP- 2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012; 1825: 29-36.
72. Iruela-Arispe ML, Carpizo D, Luque A. ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann N Y Acad Sci 2003; 995: 183-90.
73. Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 2012; 72: 2339-49.
74. van Wijngaarden J, Snoeks TJ, van Beek E, et al. An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochem Biophys Res Commun 2010; 391: 1161-5.
75. Hwang YP, Yun HJ, Choi JH, et al. Suppression of EGFinduced tumor cell migration and matrix metalloproteinase- 9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 2011; 55: 594-605.